

# 如何了解国际上在研的临床 III 期药物品种？

例)

对于自身免疫性疾病的治疗领域，检索国际上在研的 III 期药物品种。

## [1] Form Searches -Drug 检索治疗自身免疫疾病的药物，得到2007条结果。

THOMSON PHARMA®

Quick Search  as a Drug Name

Home Search Center Browse | Personalize | Folders

FORM SEARCHES

- General Text
- Clinical Trials
- Drugs**
- Intellectual Property
- Lite
- Seq
- Deals

Form Search - Drugs + EphMRA codes

Topic (Title, keywords, abstract)  Title only

Date

Update Date

- Current week
- Latest 2 weeks
- Latest 4 weeks
- Year to date

Form Search选择Drugs

Form Search - Drugs + EphMRA codes

Topic (Title, keywords, abstract)  Title only

Company

Drug

Action

Therapy area (TA)

Technology

EphMRA Code

Country

Other fields

IN  Overview

IN  Overview

IN  Overview

点击树状图标，弹出词表索引对话框

- 点击树状索引按钮，词表索引展开
- Look up 检索框输入 Autoimmune，点击 Find
- 展开索引列表后，控制词以粗体显示，点击选择控制词：

Autoimmune disease

- Immune disorder, Drugs: 4096, Patents: 39404, Deals: 1219, Protocol: 586
- Allergy, Drugs: 1551, Patents: 14298, Deals: 350, Protocol: 1377
- Immune deficiency, Drugs: 80, Patents: 3986, Deals: 32, Protocol: 1
- Lymphatic system disease, Drugs: 473, Patents: 3488, Deals: 236, Protocol: 1
- Autoimmune disease, Drugs: 2017, Patents: 22367, Deals: 662154**
- Amphospholipid syndrome, Drugs: 1, Patents: 9, Deals: 1, Protocol: 1
- Behcets disease, Drugs: 9, Patents: 148, Deals: 9, Protocol: 4
- Crohns disease, Drugs: 134, Patents: 2457, Deals: 74, Protocol: 1

自动插入控制词

**Intellectual property**  
 Include core patents

**Structure**

**Search structure as:**

Substructure

Current molecule type Exact

Similarity 80 % Min Type: Normal

Molecular weight <

---

All of the above (AND)  Any of the above (OR)

**Date limit** [Add specific date limit](#)

**点击 Search 按钮**

Search Clear Save

## [2] Rank by 按照研发阶段状态进行结果分析

**Number of Reports**

Drug 2007 DR

**Display by** ? Help

Summary

**Sort by** ? Help

Date

Ascending OR

Descending order

**Rank by** ? Help

**Display options**

Bar Chart

Pie Chart

Matrix Chart

Any dev status

Select

Analyze

← [Go to Form Search](#)

**Search Strategy**

You searched for: **My Form Search, Drugs:** "autoimmune disease"+ [Therapy Area]

**Metadata fingerprint**

Mouse over the **filter fingerprint** to display the number of records with the corresponding attribute. Click on a sector to filter the result list, retaining only records with the requested metadata attribute. Click on the center to access advanced filter options.

**Master Fingerprint**

**Filter Fingerprint**

1-20

**Summary**

**Select all** [Show Checked](#)

**abatacept**

Updated on 16-FEB-2009. Originator: Bristol-Myers Squibb Co . Highest Dev Status: Launched.

DR

**选择Any dev status**

**点击 Analyze , 进行结果分析**

## [3] 弹出窗口，显示检索结果的研发阶段状态柱形图

**Modifying the Results**  
Further modifications can be made to the chart by modifying the parameters below.

**Rank By**

Any dev status

**Set Display**

Display 20 entries

From of 16

Minimum record (threshold)

Refresh

**Export Data**


Word Excel

PDF PNG

Display Range

All Items

Export



鼠标放 Phase 3 Clinical, 显示临床 III 期药物共 118 种, 双击蓝色柱形图打开新窗口, 显示 118 种临床 III 期药物结果记录。(或选中 Phase 3 Clinical, 点击 Display)

**Number of Reports**

Drug 118

Display by Summary

**Sort by**

Date

Ascending OR Descending order


**Rank by**

Display options

Bar Chart Pie Chart Matrix Chart

Select

Go to Form Search



**Summary**

Select all Show Checked

<input checked="" type="checkbox"/>	abatacept	DR
-------------------------------------	-----------	----

Created on 10-FEB-2009. Originator: Bristol-Myers Squibb Co. Highest Dev Status: Launched

Click to open drug record

[4] 点击打开药物记录Drug Report，查看药物的全面信息：纵览，研发状态，生物学信息，化学信息，公司信息，临床试验信息等，每一个标签都可以打开阅读。

DR abatacept 1 of 118 [Back to results](#)

OVERVIEW DEVELOPMENT STATUS BIOLOGY CHEMISTRY STRATEGIC PROFILE PATENTS CLINICAL TRIALS BIBLIOGRAPHY

SUMMARY OVERVIEW DRUG NAME BREAKING NEWS DEALS

### SUMMARY

<b>Drug name</b>	abatacept
<b>Company</b>	Bristol-Myers Squibb Co
<b>Highest dev status</b>	Launched
<b>FDA Approved</b>	Juvenile Idiopathic Arthritis (Moderate To Severe), Active, Polyarticular (Pediatric), Rheumatoid Arthritis (Moderate To Severe), In Patients Who Have Had An Inadequate Response To One Or More Disease-Modifying Anti-Rheumatic Drugs (Adult)
<b>Therapy areas</b>	Scleroderma; Vasculitis; Takayasu arteritis; Psoriatic arthritis; Temporal arteritis; Multiple sclerosis; Psoriasis; Rheumatoid arthritis; Juvenile rheumatoid arthritis; Systemic lupus erythematosus; Ulcerative colitis; Transplant rejection; Graft versus host disease; Crohns disease
<b>Actions</b>	Anti-inflammatory; Immunosuppressant; T cell surface glycoprotein CD28 inhibitor
<b>Technologies</b>	Protein (conjugated); Immunoglobulin; Subcutaneous formulation; Intravenous formulation
<b>Target</b>	<a href="#">T cell surface glycoprotein CD28</a>
<b>EphMRA Code</b>	L4; M1C
<b>Update date</b>	16-FEB-2009
<b>Reason for update</b>	Minor Editorial Amendment

注：[3]后 可以选中 Phase 3 Clinical，点击 Refine，浏览哪些公司在研临床 III 期药物

Any dev status (1-16 of 16) Close

**Any dev status** ▼ **Total Results**

Development Status	Approximate Count
Launched New Formu	10
Launched New Indic	10
Launched Extensive	10
Launched	200
Registered	50
Pre-registration	50
Phase 3 Clinical	150
Phase 2 Clinical	250
Phase 1 Clinical	200
Clinical	50
Discovery	550
Withdrawn	20
Suspended	50
Research Tool	20
No Development Rep	750
Discontinued	700

**Originator (parent company) (1-20 of 83)** Close

**Originator (parent company)** **Total Results** ▼

Originator (parent company)	Count
Pfizer Inc	8
Novartis AG	5
Roche Holding AG	4
AstraZeneca plc	3
Biogen Idec Inc	3
Celgene Corp	3
GlaxoSmithKline pl	3
Isis Pharmaceutica	3
Johnson & Johnson	3
Mitsubishi Chemical	3
Adeona Pharmaceuti	2
Amgen Inc	2
Bristol-Myers Squi	2
SLA Pharma AG	2
Weizmann Institute	2
Wyeth	2
sanofi-aventis	2
Aeterna Zentaris I	1
ASAC Pharmaceutica	1
Active Biotech Ap	1

**Drug**

Select All Clear All Display Refine

点击 Refine

在研临床 III 期药物的公司列表

Display